Browse News
Filter News
Found 9 articles
-
Atavistik Bio Announces Formation of Scientific Advisory Board
9/20/2022
Atavistik Bio announced the formation of its Scientific Advisory Board (SAB).
-
Newpath is guided by the ethos: “Do the right thing and good things will happen."
-
BioSpace Movers & Shakers, Oct. 15
10/15/2021
Biopharma and life sciences companies strengthen their leadership teams and executive boards with these Movers & Shakers. -
Kojin Therapeutics Announces Luba Greenwood as Chief Executive Officer
10/14/2021
Kojin Therapeutics Announces Luba Greenwood as Chief Executive Officer
-
IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors
8/4/2021
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, announces the appointments of Emily Fairbairn and Luba Greenwood as new members of its Board of Directors.
-
Abata Therapeutics Strengthens Board of Directors
7/28/2021
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has strengthened its board of directors with the addition of Nagesh Mahanthappa Ph.D., M.B.A., and Valerie Odegard, Ph.D.
-
Money on the Move: June 9-15
6/16/2021
Each week more money pours into the biopharma world. Here's a peek at who's getting a taste of fresh funds this week. -
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
-
Kojin Therapeutics Launches with $60 Million Series A to Develop New Category of Drugs Based on Cell State Biology
6/9/2021
Kojin Therapeutics Inc., the leading company developing new targeted therapeutics based on cell state and ferroptosis biology, launched with a $60 million Series A led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital, with participation from Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.